Shorla Pharma is a pharmaceutical company developing an innovative pipeline of oncology products for unmet needs delivering a major contribution to patient care.
Shorla Pharma is reimagining lifesaving medicines for those affected by cancer.
Shorla was founded in 2018 by Sharon Cunningham and Orlaith Ryan. The company is headquartered in Dublin, Dublin, Ireland.
Shorla focuses on the development of specialised oncology drugs used to treat rare, orphan and paediatric cancers. It develops novel pharmaceutical formulations of existing treatments.
Shorla concentrates on indications where existing treatments are limited, in shortage or inadequate for the target population. Shorla completed the first good manufacturing practice production of its first sterile oncology treatment, using robotic filling technology.
Shorla Pharma has raised $8.3M (€7.4M) in Series A round of funding on June 03, 2020. Backers included Seroba Life Sciences, Clonmel, Co Tipperary, Enterprise Ireland and others.